Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DuPont de Nemours Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while DuPont de Nemours Inc trades at $132.53 (market cap $18.18B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays a 1.78% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DD | |
|---|---|---|
Market Cap | $39.89B | $18.18B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $154.59 |
52-Week Low | $278.09 | $87.72 |
Enterprise Value | $38.15B | $20.65B |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DuPont (DD) trades at $134.68, down 0.08% on the day, with a bearish technical signal and negative net income margin of -0.42% for 2025. Recent earnings have consistently beaten estimates, but revenue declined to $6.85B in 2025 from $12.4B in 2024. The company faces a lawsuit over 'forever chemicals' and completed a 3:1 reverse stock split in June 2026, while maintaining dividend payments.
The stock presents a mixed outlook: strong analyst consensus with a $227.20 price target suggests significant upside, but persistent profitability challenges and legal risks weigh on fundamentals. Investment opportunity hinges on earnings turnaround and resolution of regulatory pressures, though current technical weakness and cash flow trends indicate near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
